“…Such methods are often used to optimize conditions for mAb polishing steps involving product variant removal, and several groups have also used these techniques to design non‐mAb purification processes (Bhambure, Gupta, & Rathore, ; Kateja, Kumar, Godara, Kumar, & Rathore, ). To effectively utilize the large amount of data collected in HTS experiments and to span a wider breadth of design space, in silico techniques have been used to further inform a knowledge‐based synthesis of new downstream processes (Asenjo & Andews, ; Asenjo, Herrera, & Byrne, ; Eriksson, Sandahl, Forslund, & Österlund, ; Petrides, ; Swanson, Xu, Nettleson, & Glatz, ; Watanabe, Tsoka, & Asenjo, ; Winkelnkemper & Schembecker, ; Winkelnkemper & Schembecker, ). Reported strategies, however, often rely on time‐consuming proteomic analysis of host cell proteins (HCPs), extensive characterization of the biophysical or biochemical attributes of the proteins, or tracking of individual impurities (Hanke & Ottens, ; Hanke et al, ).…”